Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MRG004A |
Synonyms | |
Therapy Description |
MRG004A is an antibody-drug conjugate consisting of an anti-tissue factor (TF) monoclonal antibody conjugated to monomethyl auristatin E (MMAE), which may lead to G2/M cell cycle arrest and apoptosis of tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MRG004A | MRG-004A|MRG 004A | MRG004A is an antibody-drug conjugate consisting of an anti-tissue factor (TF) monoclonal antibody conjugated to monomethyl auristatin E (MMAE), which may lead to G2/M cell cycle arrest and apoptosis of tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04843709 | Phase Ib/II | MRG004A | A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |